Affordable Access

Publisher Website

Immunomodulating drugs for chronic lymphocytic leukaemia

Authors
Journal
The Lancet Oncology
1470-2045
Publisher
Elsevier
Publication Date
Volume
7
Issue
6
Identifiers
DOI: 10.1016/s1470-2045(06)70723-9
Keywords
  • Review And Opinion
  • Review
Disciplines
  • Medicine

Abstract

Summary Chronic lymphocytic leukaemia (CLL) is a malignant haematological disorder that remains mostly incurable; more than 95% of patients have disease of B-cell origin. Advances with targeted agents such as monoclonal antibodies, antisense therapy, or both these techniques combined with traditional chemotherapy have improved the frequency of remission. The clinical course of CLL is marked by frequent relapse, and there are limited therapeutic options for patients with relapsed or refractory disease. The morphologically mature CLL clone regulates the microenvironment through modulation of the cytokine milieu that aids its growth and survival, and has a role in immune escape. Targeting of the tumour-cell microenvironment has not been investigated as a treatment option for CLL. Immunomodulating agents are a new class of drugs that change expression of various cytokines and that costimulate immune effector cells.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Emerging drugs for chronic lymphocytic leukaemia.

on Expert opinion on emerging dru... March 2006

Chronic lymphocytic leukaemia--new drugs and manag...

on Journal of the Royal College o... 1995

Transient leukaemia cutis in chronic lymphocytic l...

on Clinical and experimental derm... January 1997
More articles like this..